Paediatric and adult bronchiectasis

Monitoring, cross-infection, role of multidisciplinary teams and self-management plans

Vidya Navaratnam, Douglas L. Forrester, Kah Peng Eg, Anne B. Chang

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Bronchiectasis is a chronic lung disease associated with structurally abnormal bronchi, clinically manifested by a persistent wet/productive cough, airway infections and recurrent exacerbations. Early identification and treatment of acute exacerbations is an integral part of monitoring and annual review, in both adults and children, to minimize further damage due to infection and inflammation. Common modalities used to monitor disease progression include clinical signs and symptoms, frequency of exacerbations and/or number of hospital admissions, lung function (forced expiratory volume in 1 s (FEV1)% predicted), imaging (radiological severity of disease) and sputum microbiology (chronic infection with Pseudomonas aeruginosa). There is good evidence that these monitoring tools can be used to accurately assess severity of disease and predict prognosis in terms of mortality and future hospitalization. Other tools that are currently used in research settings such as health-related quality of life (QoL) questionnaires, magnetic resonance imaging and lung clearance index can be burdensome and require additional expertise or resource, which limits their use in clinical practice. Studies have demonstrated that cross-infection, especially with P. aeruginosa between patients with bronchiectasis is possible but infrequent. This should not limit participation of patients in group activities such as pulmonary rehabilitation, and simple infection control measures should be carried out to limit the risk of cross-transmission. A multidisciplinary approach to care which includes respiratory physicians, chest physiotherapists, nurse specialists and other allied health professionals are vital in providing holistic care. Patient education and personalized self-management plans are also important despite limited evidence it improves QoL or frequency of exacerbations.

    Original languageEnglish
    Pages (from-to)115-126
    Number of pages12
    JournalRespirology
    Volume24
    Issue number2
    Early online date30 Nov 2018
    DOIs
    Publication statusPublished - Feb 2019

    Fingerprint

    Bronchiectasis
    Self Care
    Cross Infection
    Pediatrics
    Lung
    Pseudomonas aeruginosa
    Infection
    Quality of Life
    Patient Participation
    Allied Health Personnel
    Physical Therapists
    Forced Expiratory Volume
    Patient Education
    Bronchi
    Infection Control
    Microbiology
    Sputum
    Cough
    Lung Diseases
    Signs and Symptoms

    Cite this

    Navaratnam, Vidya ; Forrester, Douglas L. ; Eg, Kah Peng ; Chang, Anne B. / Paediatric and adult bronchiectasis : Monitoring, cross-infection, role of multidisciplinary teams and self-management plans. In: Respirology. 2019 ; Vol. 24, No. 2. pp. 115-126.
    @article{ea86d56936e642ac93a268ab2bbe628d,
    title = "Paediatric and adult bronchiectasis: Monitoring, cross-infection, role of multidisciplinary teams and self-management plans",
    abstract = "Bronchiectasis is a chronic lung disease associated with structurally abnormal bronchi, clinically manifested by a persistent wet/productive cough, airway infections and recurrent exacerbations. Early identification and treatment of acute exacerbations is an integral part of monitoring and annual review, in both adults and children, to minimize further damage due to infection and inflammation. Common modalities used to monitor disease progression include clinical signs and symptoms, frequency of exacerbations and/or number of hospital admissions, lung function (forced expiratory volume in 1 s (FEV1){\%} predicted), imaging (radiological severity of disease) and sputum microbiology (chronic infection with Pseudomonas aeruginosa). There is good evidence that these monitoring tools can be used to accurately assess severity of disease and predict prognosis in terms of mortality and future hospitalization. Other tools that are currently used in research settings such as health-related quality of life (QoL) questionnaires, magnetic resonance imaging and lung clearance index can be burdensome and require additional expertise or resource, which limits their use in clinical practice. Studies have demonstrated that cross-infection, especially with P. aeruginosa between patients with bronchiectasis is possible but infrequent. This should not limit participation of patients in group activities such as pulmonary rehabilitation, and simple infection control measures should be carried out to limit the risk of cross-transmission. A multidisciplinary approach to care which includes respiratory physicians, chest physiotherapists, nurse specialists and other allied health professionals are vital in providing holistic care. Patient education and personalized self-management plans are also important despite limited evidence it improves QoL or frequency of exacerbations.",
    keywords = "cross-infection, disease monitoring, multidisciplinary team, non-cystic fibrosis bronchiectasis, paediatric bronchiectasis",
    author = "Vidya Navaratnam and Forrester, {Douglas L.} and Eg, {Kah Peng} and Chang, {Anne B.}",
    year = "2019",
    month = "2",
    doi = "10.1111/resp.13451",
    language = "English",
    volume = "24",
    pages = "115--126",
    journal = "Respirology",
    issn = "1323-7799",
    publisher = "Wiley-Blackwell",
    number = "2",

    }

    Paediatric and adult bronchiectasis : Monitoring, cross-infection, role of multidisciplinary teams and self-management plans. / Navaratnam, Vidya; Forrester, Douglas L.; Eg, Kah Peng; Chang, Anne B.

    In: Respirology, Vol. 24, No. 2, 02.2019, p. 115-126.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Paediatric and adult bronchiectasis

    T2 - Monitoring, cross-infection, role of multidisciplinary teams and self-management plans

    AU - Navaratnam, Vidya

    AU - Forrester, Douglas L.

    AU - Eg, Kah Peng

    AU - Chang, Anne B.

    PY - 2019/2

    Y1 - 2019/2

    N2 - Bronchiectasis is a chronic lung disease associated with structurally abnormal bronchi, clinically manifested by a persistent wet/productive cough, airway infections and recurrent exacerbations. Early identification and treatment of acute exacerbations is an integral part of monitoring and annual review, in both adults and children, to minimize further damage due to infection and inflammation. Common modalities used to monitor disease progression include clinical signs and symptoms, frequency of exacerbations and/or number of hospital admissions, lung function (forced expiratory volume in 1 s (FEV1)% predicted), imaging (radiological severity of disease) and sputum microbiology (chronic infection with Pseudomonas aeruginosa). There is good evidence that these monitoring tools can be used to accurately assess severity of disease and predict prognosis in terms of mortality and future hospitalization. Other tools that are currently used in research settings such as health-related quality of life (QoL) questionnaires, magnetic resonance imaging and lung clearance index can be burdensome and require additional expertise or resource, which limits their use in clinical practice. Studies have demonstrated that cross-infection, especially with P. aeruginosa between patients with bronchiectasis is possible but infrequent. This should not limit participation of patients in group activities such as pulmonary rehabilitation, and simple infection control measures should be carried out to limit the risk of cross-transmission. A multidisciplinary approach to care which includes respiratory physicians, chest physiotherapists, nurse specialists and other allied health professionals are vital in providing holistic care. Patient education and personalized self-management plans are also important despite limited evidence it improves QoL or frequency of exacerbations.

    AB - Bronchiectasis is a chronic lung disease associated with structurally abnormal bronchi, clinically manifested by a persistent wet/productive cough, airway infections and recurrent exacerbations. Early identification and treatment of acute exacerbations is an integral part of monitoring and annual review, in both adults and children, to minimize further damage due to infection and inflammation. Common modalities used to monitor disease progression include clinical signs and symptoms, frequency of exacerbations and/or number of hospital admissions, lung function (forced expiratory volume in 1 s (FEV1)% predicted), imaging (radiological severity of disease) and sputum microbiology (chronic infection with Pseudomonas aeruginosa). There is good evidence that these monitoring tools can be used to accurately assess severity of disease and predict prognosis in terms of mortality and future hospitalization. Other tools that are currently used in research settings such as health-related quality of life (QoL) questionnaires, magnetic resonance imaging and lung clearance index can be burdensome and require additional expertise or resource, which limits their use in clinical practice. Studies have demonstrated that cross-infection, especially with P. aeruginosa between patients with bronchiectasis is possible but infrequent. This should not limit participation of patients in group activities such as pulmonary rehabilitation, and simple infection control measures should be carried out to limit the risk of cross-transmission. A multidisciplinary approach to care which includes respiratory physicians, chest physiotherapists, nurse specialists and other allied health professionals are vital in providing holistic care. Patient education and personalized self-management plans are also important despite limited evidence it improves QoL or frequency of exacerbations.

    KW - cross-infection

    KW - disease monitoring

    KW - multidisciplinary team

    KW - non-cystic fibrosis bronchiectasis

    KW - paediatric bronchiectasis

    UR - http://www.scopus.com/inward/record.url?scp=85057623716&partnerID=8YFLogxK

    U2 - 10.1111/resp.13451

    DO - 10.1111/resp.13451

    M3 - Article

    VL - 24

    SP - 115

    EP - 126

    JO - Respirology

    JF - Respirology

    SN - 1323-7799

    IS - 2

    ER -